Alka Khera
Neurology · Dallas, TXNPI 1073909503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 33.9% of the total. That places this record below the midpoint for neurology clinicians in TX, where the typical reported total is $2,170.
Across 4 payments — averaging $86.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$117
- Biogen$115
- F. Hoffmann-la Roche AG$80
- Lilly USA, LLC$33
Across 15 payments — averaging $43,134 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$367K
- Eli Lilly$219K
- Genentech, Inc.$42K
- AbbVie$20K
What the payments were for
- Food & beverage$346100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| Biogen | 1 | $115 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Lilly USA, LLC | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$117
How this compares
$346 in reported general payments places this provider in the 25th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 64 | $16,812 |
| Memantine Hcl | 375 | $10,443 |
| Galantamine ErGalantamine Hbr | 100 | $8,169 |
| Donepezil Hcl | 555 | $7,106 |
| Memantine Hcl ErMemantine Hcl | 30 | $6,112 |
| Sertraline Hcl | 165 | $1,370 |
| Mirtazapine | 45 | $1,223 |
| Levetiracetam | 25 | $557 |
| Duloxetine Hcl | 15 | $332 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 14 | $182 |
| Trazodone Hcl | 30 | $169 |
| Quetiapine Fumarate | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.